Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +50

Gilead Sciences Balances Strong Growth With EPS Hit

AI-generated analysis

πŸ“ˆ Gilead Sciences reported Q1 total product sales of $6.9 billion, a 5% year-over-year increase, with underlying sales rising 8% excluding the COVID drug Veklury.

πŸš€ Management lifted its 2026 revenue outlook by $400 million, forecasting base business sales between $29.4 and $29.8 billion and total product sales from $30.0 to $30.4 billion.

πŸ’Š The HIV portfolio remained a primary growth engine with sales climbing 10% to $5.0 billion, led by Biktarvy which holds over 52% U.S. market share.

πŸ”¬ Oncology segment momentum continued with Trodelvy sales rising 37% year-over-year and the Tubulis acquisition adding a differentiated ADC platform.

πŸ’‰ The liver disease portfolio saw a successful launch of Libdelzi, generating $133 million in Q1 by capturing over half of the U.S. second-line primary biliary cholangitis market.

🏦 Core profitability remained strong with product gross margin improving to 87% and non-GAAP diluted EPS rising 12% to $2.03 supported by a 47% operating margin.

πŸ’° The company returned more than $1.4 billion to shareholders in the quarter through share repurchases and dividends, representing roughly 60% of free cash flow.

🧬 Gilead expanded its pipeline to 47 clinical programs following the closing of the Arcellx deal and pending acquisitions of Oral Medicines and Tubulis.

πŸ’Έ Reported EPS faces pressure from approximately $11.5 billion to $11.8 billion in upfront intellectual property and R&D charges related to recent deals.

πŸ“‰ Management guided to a full-year non-GAAP loss per share of $1.05 to $0.65 due to transaction impacts, masking an underlying EPS range of $8.45 to $8.85.

πŸ’Ή Gilead expects an unusually high effective tax rate ranging from 140% to 190% for the year driven by nondeductible expenses from major acquisitions.

πŸ“Š Sequentially, total product sales fell 12% as management attributed the decline to standard Q1 seasonality and inventory drawdowns rather than demand weakness.

πŸ›‘οΈ Cell therapy revenue dropped to $407 million, down 12% year-over-year, amid intensified competition in new treatments across several regions.

πŸ“‰ Operating expenses increased with SG&A rising 12% year over year as the company pursues strategic growth initiatives and deal expansions.

🎯 Kite unit will host anitocel, which offers differentiated efficacy for multiple myeloma and targets a $3.5 billion market opportunity in fourth-line-plus CAR-T therapies.

πŸ“… Upcoming milestones include FDA decisions for Biclen, anitocel, and bulevirtide, alongside Phase 3 updates expected during the second half of 2026.

Full Analysis
Gilead Sciences (GILD) reported mixed results for its Q1 earnings call, highlighting strong operational growth that was counterbalanced by significant non-recurring charges and unusual tax effects dragging reported earnings per share into the red. The company delivered total product sales of $6.9 billion, representing a 5% year-over-year increase, while excluding revenue from the COVID drug Veklury, organic growth accelerated to 8%. This performance prompted management to raise its full-year base business sales guidance to between $29.4 billion and $29.8 billion, along with lifting total product sales expectations by approximately $400 million compared to prior forecasts. Key segments showed robust momentum, particularly in HIV where sales rose 10% to $5.0 billion driven largely by Biktarvy and a surging PrEP business that jumped 87%. The oncology franchise also strengthened with Trodelvy sales climbing 37% to $402 million as it gained approval in triple-negative breast cancer, while the recent Tubulis acquisition added promising assets for ovarian cancer. Additionally, the liver disease portfolio saw Libdelzi generate $133 million in the quarter and capture over half of its U.S. primary biliary cholangitis market, with management projecting an IDEAL Phase 3 update later this year to support further label expansion. Despite these operational wins, the company faces a reported loss due to large upfront transaction costs associated with recent acquisitions including Arcellx, Oral Medicines, and Tubulis, estimated at roughly $11.5 billion to $11.8 billion for the year. These expenses, combined with a highly unusual 140% to 190% effective tax rate driven by nondeductible costs, guided Gilead to a full-year non-GAAP loss per share of between -$1.05 and $-0.65, significantly distorting from an underlying EPS range of $8.45 to $8.85. However, core profitability remained intact with gross margins improving to 87% and non-GAAP diluted EPS rising 12% to $2.03.